MedAlliance Swiss Medical Technology

UNCAGE | Uncaging Coronaries with Metal Free PCI – An interactive medical education series on treating coronaries with sirolimus drug-eluting balloons.

Join us on November 23rd at 17:00 CET, for UNCAGE episode 3:
UNCAGE Coronaries, UNCAGE Chronic Total Occlusions

Moderator: Dr. Daniel Weilenmann
Panel:
- Dr. Kambis Mashayekhi
- Dr. Florim Cuculi

Register now at the following link: https://bit.ly/3fO7QO4

We look forward to your participation!

Latest and greatest in Vegas!

MedAlliance is delighted to head back to sin city and excited to share 24 months CLTI clinical results at 2022!

Late Breaking Trial Session, November 2nd 11:00pm (UTC-7)
Utility Of Sirolimus Drug Eluting Balloons in the Treatment of Complex Below-The-Knee Atherosclerotic Disease in Patients with Chronic Limb Threatening Ischemia – 24months Results from the PRESTIGE Study. – Dr T. Tang

The MedAlliance team is looking forward to your participation and discussions with you on our latest results!

What happens in Vegas…. will spread out of Vegas!

MedAlliance is extremely happy to announce that we have entered into an agreement with Cordis for an acquisition.

MedAlliance's innovative and revolutionary sustained sirolimus drug eluting balloon (DEB) program, SELUTION SLR™ (Sustained Limus Release), will provide a flagship product family which will complements Cordis' existing product portfolio.

Cordis customers will benefit from our extensive clinical study program and publication to further Cordis' heritage of bringing innovative products that will patients around the world.

We will immediately start Collaborating with Cordis on co-promotion our MedAlliance’s SELUTION SLR™ drug-eluting balloon in markets where it is commercially available.

To view press release: https://medalliance.com/2022/10/18/medalliance-to-be-acquired-by-cordis/

Next stop. !

We are delighted to announce that MedAlliance will showcase its breakthrough technology SELUTION SLR with two exciting clinical trials actively enrolling.

Tuesday 20th Sept,

Prize Fast Track Session ; Plenary 1 - 14:18 CET
Dr. Michael Lichtenberg: Interim Report of the SUCCESS PTS Study Evaluating Safety and Efficacy of the Novel Sirolimus-eluting SELUTION SLR Balloon in Peripheral Arterial Disease

Fast-Track Session 6: Plenary 7 - 14:12 CET
Dr. Aloke Finn: Novel Sirolimus-eluting Balloon Technology With Non-crystalline Drug Formulation- Distal Embolization Study.

Our MedAlliance team is thrilled to see you there and looking forward to your input.

MedAlliance will be present at .

Expanding usage of drug coated balloons in broader indications will be debated in Boston this weekend.
We will have the pleasure to showcase ’s advanced technology and state of the art clinical program, please come and partake in the following discussions.

Sat 17th September

Global Spotlights and hot topics: Coronary Drug Coated Balloons: Program Updates and Future Applications
Sirolimus DCBs: Technological Trends, Challenges and Advantages by Dr. Alexandre Abizaid at 8:56 AM.
Stent-Free PCI (DCB Only Approach): Insights and Considerations from the SELUTION DeNovo Randomized Control Study by Pr. Christian Spaulding at 9:04 AM.

Featured Clinical Research: Sustained Limus Release vs Paclitaxel DCB Treatment in Symptomatic Peripheral Artery Disease: The Limus FLOW Investigator-Initiated, Randomized Controlled Trial by Pr. Christos Rammos, MHBA, FESC at 4:30 PM.

Sun 18th September
Emerging Clinical Science and Research- DCB I: Impact of Scoring Balloons on Drug Absorption Prior to Drug-coated Balloon Deployment- a Cadaver-based Study by John E. Shulze (CTO MedAlliance) at 10:12 AM.

Our MedAlliance team is excited to see you in Boston !!

Medalliance is present at CIRSE - Cardiovascular and Interventional Radiological Society of Europe 22' !

Please come and attend the session, Clinical Trials in Vascular Intervention: Meet the PI
(Session: MPI 401)

Join the discussion with Dr. Michael Lichtenburg, Pr. Christos Rammos and Pr. Marianne Brodmann, Saturday 10th September from 13:00 to 14:00 CET, News on Stage.
Dr. Lichtenburg will have the pleasure to present for the first time interim results for our SUCCESS clinical trial.
Pr. Rammos will present the Limus FLOW investigator-initiated study.
Pr. Brodmann, as the European Principal Investigator, will present SELUTION4BTK FDA IDE clinical trial that has just been approved and its first patients have already been enrolled in the US and Europe.

We look forward to seeing you there !

We are truly delighted to announce that the first US patient has been enrolled in the SELUTION4BTK (Below- the- Knee) FDA IDE Study. This is a major achievement as MedAlliance becomes the first company to enroll the very first US patient in a sirolimus DCB study.

“We are very excited to finally have drug-eluting technology in the US to treat this difficult patient population”, commented the trial’s Principal Investigator (PI) Dr. Ehrin Armstrong. “We are encouraged by the positive early outcomes with this novel SELUTION SLR Sirolimus Drug Eluting Balloon (DEB) in Europe and Asia. We hope this FDA IDE trial will demonstrate significant benefit for patients that currently have limited treatment options.”

More information to be shared soon.

To view press release click here: https://bit.ly/3CtPr22

We are excited to announce that SELUTION SLR™ has received its second FDA Investigational Device Exemption (IDE) approval for the SELUTION4SFA study, a pivotal clinical trial for treatment of the occlusive disease for the Superficial Femoral Artery (SFA). SELUTION SLR™ is the only Sirolimus-Eluting Balloon to receive two FDA IDE approvals.

“We are very excited that US patients suffering from PAD will have the opportunity to receive this novel sirolimus drug coated balloon technology. This is yet another advancement in the field of treating vascular disease and we are confident that this study will enroll quickly”, Dr. George Adams commented.

Click here to read the full press release: https://bit.ly/3PoDFc4

We are very pleased to announce the first German patient randomized in the SELUTION DeNovo study at Fürst-Stirum-Klinik Bruchsal.

SELUTION DeNovo is a unique treatment strategy trial randomizing DEB vs. DES in an all-comers population.
• More than 3,3000 patients to be enrolled
• 50+ International clinical sites

Thank you Prof. Martin Andrassy and your team for your support with this unique clinical trial!

To learn more about the SELUTION DeNovo Study, click on the following link: https://bit.ly/3t643OA

2 days left until UNCAGE Episode 2: UNCAGE Bifurcations, Make the complex simple - A case-based discussion.

Join the session with Prof. Alexandre Abizaid, Dr. Carlo Briguori, Dr. Sophie Degrauwe, and Dr. Simon Eccleshall.

Register now for July 6th - 18:00 CET at the following link: https://bit.ly/3mZvyqT

We look forward to your participation!

MedAlliance is present at MLCTO 2022, starting tomorrow in Nice, France at Palais de la Méditerranée!

Join session #4 from 16:30 to 18:30 CET to see a CTO case performed with SELUTION SLR™, presented by Dr. Daniel Weilenmann.

We look forward to your participation!

UNCAGE | Uncaging Coronaries with Metal Free PCI – An interactive medical education series on treating coronaries with sirolimus drug-eluting balloons.

Join us on July 6th at 18:00 CET, for UNCAGE episode 2:
UNCAGE Bifurcations, Make the complex simple - A case-based discussion

Moderator: Alexandre Abizaid
Panel:
- Carlo Briguori
- Sophie Degrauwe
- Simon Eccleshall

Register now at the following link: https://bit.ly/3mZvyqT

We look forward to your participation!

We are very pleased to announce that last week, the UK started to enroll patients in the SELUTION DeNovo Study at Glenfield Hospital and Royal Berkshire Hospital!

Thank you Prof. Neil Ruparelia & Dr. Andrew Ladwiniec for your support with this study.

The SELUTION DeNovo Study is the largest DEB study ever initiated, with over 3,300 patients to be enrolled at approximately 50 sites in 15 countries. Patients are randomized in DEB vs. DES arms before any vessel preparation. The objectives of the study are to demonstrate, at both one and five years, non-inferiority and potentially superiority in terms of target vessel failure (TVF).

To learn more about the SELUTION DeNovo Study, click on the following link: https://bit.ly/3t643OA

Thank you all for a great LINC 2022 in Leipzig, Germany!

We were happy to welcome you to our booth and showcase the latest news on SELUTION SLR™. Thank you to the LINC Organization for making this congress possible!

We look forward to seeing you all again next year!

Our Case-in-Point Session at EuroPCR 2022 is now available on our YouTube Channel!

Watch the full session on redefining indications for Drug-Eluting Balloons in COMPLEX PCI – The Role of Sustained Limus Release at the following link: https://bit.ly/3xLKf75

Thank you to the chairman, Antonio Colombo, and panelists, Barbara E. Stähli, Hee Hwa Ho, Joanna Wykrzykowska, Kambis Mashayekhi, Sudhir Rathore, and Quentin Chatelain for supporting this session.

Redefining Indications for Drug-Eluting Balloons in COMPLEX PCI - EuroPCR 2022 In this session, learn how sustained limus release technology can broaden DEB indications, learn about the decision-making process on the use of DEB adjacent...

We are excited to announce that the first patient has just been enrolled in the SELUTION4BTK study, just one week after receiving FDA Investigational Device Exemption (IDE) approval.

The aim of the SELUTION4BTK clinical trial is to demonstrate the superior efficacy and equivalent safety of SELUTION SLR compared to plain (uncoated) balloon angioplasty (POBA) in the treatment of BTK arteries in CLTI (Chronic Limb Threatening Ischemia) patients. The trial is a prospective, multi-center, single-blinded, randomized study.

“I am excited to begin an important trial which will establish the evidence that this novel technology benefit patients suffering from CLTI”, commented Dr. Michael Lichtenberg, Chief of the Angiology Department at the Klinikum Hochsauerland, Arnsberg, Germany. “So far nothing has worked consistently in this patient population. The early clinical data from SELUTION SLR registries are encouraging and I have seen the performance of this new technology in my routine work. This study is designed to prove that SELUTION SLR is more effective than the current standard of care in this difficult patient population”.

Click here to read the full press release: https://bit.ly/3H1YUxS

Click here to learn more about the FDA IDE Approval: https://prn.to/3Nm8UVd

LINC 2022 has started!

We look forward to meeting you at booth #44 to share with you the latest news on SELUTION SLR™

SELUTION SLR new data release at LINC 2022!

6 months results of the PRISTINE Registry– Utility of Sirolimus Eluting Balloon in the treatment of complex infra—inguinal atherosclerotic disease in patients with chronic threatening ischemia.

Come and attend the presentation from Dr. Tjun Tang on Wednesday June 8th, 2022 at 13:40 in the Room 3 – Speakers’ Corner

We look forward to seeing you there!

MedAlliance is present at LINC 2022!

Save a limb to save a life - New horizons with Sirolimus-eluting balloons in treating CLI patients – global experience

Join the discussion with Ehrin Armstrong, Michael Lichtenberg, Bella Huasen, Luis Palena, and Tjun Yip Tang, Tuesday 7th June 2022 from 16:00 to 16:45 CET in Room 1, Main Arena 1

We look forward to seeing you there!

Day 3 at EuroPCR 2022!

Don’t forget to join our Late Breaking Trial today at 10.45h CET in room Maillot, where Dr. Praveen Chandra will present new clinical results with SELUTION SLR™ Technology.

We look forward to seeing you there!

Day 2 at EuroPCR 2022!

Don’t forget to join our Case-in-Point session today from 12.15h to 13.00 CET in room 252B on Redefining Indications for Drug-Elution Balloons in COMPLEX PCI - The Role of Sustained Limus Release.

Thank you to the chairman, Antonio Colombo, and the panelists, Barbara E. Stähli, Hee Hwa Ho, Joanna Wykrzykowska, Kambis Mashayekhi, SUDHIR RATHORE, and Quentin Chatelain for supporting this session.

We look forward to seeing you there!

Ready for the show, let PCR start!

Come visit us at booth on Level 2.






PCRonline

Champions LImb | Winning the challenge against CLI

Join us Tuesday, 24th of May at 16:00 CET, for the second Champions LImb episode.

Running the line - Distal BTK & pedal arteries, a case-based discussion

Join the discussion with Theodosios Bisdas, Marianne Brodmann, Bella Huasen, Tjun Tang

To participate, create your personal Vascupedia account at https://lnkd.in/dg4-N79 and use your email address and password to login to web.liveroundtable.app or the Vascupedia LIVE App.

We look forward to your participation!

MedAlliance is present at EuroPCR 2022 at the Palais des Congrès in Paris from Tuesday, May 17th, to Friday, May 20th.

We look forward to welcoming you at booth , on level 2, to share with you the latest news on SELUTION SLR™.

We hope to see you there!

To learn more about our participation at EuroPCR 2022, please click on the following link: https://bit.ly/3L4tAil

Dr. Praveen Chandra, Interventional Cardiologist at Medanta – The Medicity, will present at EuroPCR 2022 new clinical results with SELUTION SLR™ Technology in coronary lesions.

Presentation: Sirolimus-coated balloon with micro-reservoir technology in coronary lesions

Come and see the presentation on Thursday 19th of May, at 10.45h CET in Room Maillot.

We look forward to seeing you there!

To learn more about our participation at EuroPCR 2022, please click on the following link: https://bit.ly/3L4tAil

Join our Case-in-Point Session at EuroPCR 2022 on Wednesday 18th of May from 12.15h to 13.00h CET in room 252B.

The primary topic of this session is about redefining indications for Drug-Eluting Balloons in COMPLEX PCI – The Role of Sustained Limus Release

Thank you to the chairman, Antonio Colombo, and the panelists, Barbara E. Stähli, Hee Hwa Ho, Joanna Wykrzykowska, Kambis Mashayekhi, Sudhir Rathore, and Quentin Chatelain for supporting this session.

We look forward to seeing you there!

# #

MedAlliance at Charing Cross 2022!

Don’t miss our session at CX22, this Thursday, from 11:20 AM to 11:25 AM (BST). John Shulze, MedAlliance’s Chief Technology Officer, will give a talk on optimizing DCB coating design and drug selection.

To learn more about the latest news on SELUTION SLR™ and its unique technology, we welcome you to booth #17. Our team would be happy to meet you!

We hope to see you there!